SCHEMBL5607372

SCHEMBL5607372

COc1ccccc1Oc1ccc(Br)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.52
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA14 Q9ULX7 2/20 0.52
CA4 P22748 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HTT P42858 3/20 0.52
MAPK1 P28482 2/20 0.52
TDP1 Q9NUW8 1/20 0.48
AR P10275 1/20 0.46
DHPS P49366 1/20 0.45
APP P05067 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1129135 0.89 AR (0.60) CA2CA12CA1CA7CA9
SCHEMBL1129397 0.88 MAPT (0.48) L3MBTL1ALDH1A1MAPK1TDP1AR
SCHEMBL5606658 0.88 TP53 (0.55) CA2CA1L3MBTL1ALDH1A1HTT
SCHEMBL29419589 0.87 CA2 (0.56) CA2CA12CA1CA7CA9
SCHEMBL20509 0.87 CA2 (0.56) CA2CA12CA1CA7CA9
SCHEMBL1256865 0.85 CA2 (0.54) CA2CA12CA1CA7CA9
SCHEMBL1129837 0.85 TTR (0.58) L3MBTL1ALDH1A1HTTMAPK1MEN1
SCHEMBL5606856 0.84 ALDH1A1 (0.54) ALDH1A1HTTTDP1ARMEN1
Ethyne SCHEMBL28045684 0.83 CA2 (0.52) CA2CA12CA1CA7CA9
Methyl Alcohol SCHEMBL28799088 0.83 CA2 (0.52) CA2CA12CA1CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106946875-B A kind of preparation method for the imidazole heterocyclic compounds that C-3 oxygen replaces 杭州师范大学 2019-05-17 CN disclosed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 CA2 2590/4885CA12 4468/4885CA1 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.